阿帕替尼联合化疗治疗晚期乳腺癌的疗效及安全性分析

Analysis of efficacy and safety of apatinib combined with chemotherapy in the treatment of advanced breast cancer

目的:探讨阿帕替尼联合化疗治疗晚期乳腺癌的疗效及安全性。方法:2018年1月-2020年10月收治晚期乳腺癌患者60例,随机分为两组,各30例。对照组使用化疗治疗;观察组使用阿帕替尼联合化疗治疗。比较两组患者不同方法治疗后治疗效率与疾病控制率、不良反应发生情况、血小板第四因子(PF4)与midkine(中期因子)中期因子(MK)指标变化情况,应用癌症患者生命质量测定量表(EORTC QLQ-C30)对患者生命质量进行评估。结果:观察组治疗总有效率及疾病控制率均明显高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组治疗后血清MK及PF4水平均明显低于对照组,差异有统计学意义(P<0.05);观察组治疗后EORTC QLQ-C30评分明显高于对照组,差异有统计学意义(P<0.05)。结论:阿帕替尼联合化疗治疗晚期乳腺癌的疗效显著,安全性高,明显降低血清MK、PF4水平,抑制肿瘤血管新生,且能明显提升患者生活质量。

Objective:To explore the efficacy and safety of apatinib combined with chemotherapy in the treatment of advanced breast cancer.Methods:From January 2018 to October 2020,60 patients with advanced breast cancer were selected and randomly divided into two groups with 30 cases in each group.The control group was treated with chemotherapy.The observation group was treated with apatinib combined with chemotherapy.The treatment efficiency,disease control rate,adverse reactions,changes of platelet factor 4(PF4)and midkine(MK)were compared between the two groups.The quality of life of patients with cancer was evaluated by EORTC QLQ-C30.Results:The total effective rate and disease control rate in the observation group were significantly higher than the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions was compared between the two groups,the difference was not statistically significant(P>0.05).The levels of serum MK and PF4 in the observation group were significantly lower than the control group after treatment,the differences were statistically significant(P<0.05).The EORTC QLQ-C30 score of the observation group was significantly higher than the control group after treatment,the difference was statistically significant(P<0.05).Conclusion:Apatinib combined with chemotherapy has significant efficacy and high safety in the treatment of advanced breast cancer,which can significantly reduce the levels of serum MK and PF4,inhibit tumor angiogenesis,and significantly improve the quality of life of patients.